CO6190511A2 - 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 - Google Patents

2-fenilindoles como antagonistas del receptor de la prostaglandina d2

Info

Publication number
CO6190511A2
CO6190511A2 CO09002745A CO09002745A CO6190511A2 CO 6190511 A2 CO6190511 A2 CO 6190511A2 CO 09002745 A CO09002745 A CO 09002745A CO 09002745 A CO09002745 A CO 09002745A CO 6190511 A2 CO6190511 A2 CO 6190511A2
Authority
CO
Colombia
Prior art keywords
phenylethyl
hydrogen
chloro
dichloro
methoxy
Prior art date
Application number
CO09002745A
Other languages
English (en)
Spanish (es)
Inventor
Zhaoxia Yang
Stephan Reiling
Thaddeus R Nieduzak
Rose M Mathew
Sharon Jackson
Keith John Harris
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6190511A2 publication Critical patent/CO6190511A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CO09002745A 2006-07-25 2009-01-15 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 CO6190511A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82029906P 2006-07-25 2006-07-25
US82030106P 2006-07-25 2006-07-25
US82030206P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
CO6190511A2 true CO6190511A2 (es) 2010-08-19

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09002745A CO6190511A2 (es) 2006-07-25 2009-01-15 2-fenilindoles como antagonistas del receptor de la prostaglandina d2

Country Status (25)

Country Link
US (1) US20090176804A1 (cg-RX-API-DMAC7.html)
EP (1) EP2066628B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009544721A (cg-RX-API-DMAC7.html)
KR (1) KR20090039735A (cg-RX-API-DMAC7.html)
AR (1) AR062051A1 (cg-RX-API-DMAC7.html)
AT (1) ATE485270T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007276885A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714554A2 (cg-RX-API-DMAC7.html)
CA (1) CA2659055A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO6190511A2 (cg-RX-API-DMAC7.html)
CR (1) CR10577A (cg-RX-API-DMAC7.html)
DE (1) DE602007010010D1 (cg-RX-API-DMAC7.html)
DK (1) DK2066628T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099087A (cg-RX-API-DMAC7.html)
GT (1) GT200900016A (cg-RX-API-DMAC7.html)
IL (1) IL196587A0 (cg-RX-API-DMAC7.html)
MA (1) MA30643B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009000830A (cg-RX-API-DMAC7.html)
NO (1) NO20090862L (cg-RX-API-DMAC7.html)
PE (1) PE20080549A1 (cg-RX-API-DMAC7.html)
PT (1) PT2066628E (cg-RX-API-DMAC7.html)
TN (1) TNSN08515A1 (cg-RX-API-DMAC7.html)
TW (1) TW200821286A (cg-RX-API-DMAC7.html)
WO (1) WO2008014186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072576A1 (ja) * 2007-12-04 2009-06-11 Sapporo Breweries Limited 骨形成促進剤
RS52809B (sr) * 2008-11-17 2013-10-31 F. Hoffmann-La Roche Ag. Naftilsirćetne kiseline
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
PH12016501764B1 (en) 2014-03-17 2024-05-17 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CN112384497A (zh) 2018-05-09 2021-02-19 格卢科克斯生物科技有限公司 具有选择性nox抑制活性的新型磺酰胺衍生物
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Also Published As

Publication number Publication date
PE20080549A1 (es) 2008-06-20
ECSP099087A (es) 2009-02-27
CR10577A (es) 2009-03-20
WO2008014186A1 (en) 2008-01-31
PT2066628E (pt) 2010-12-31
TNSN08515A1 (en) 2010-04-14
DE602007010010D1 (de) 2010-12-02
JP2009544721A (ja) 2009-12-17
CL2007002163A1 (es) 2008-02-08
EP2066628B1 (en) 2010-10-20
BRPI0714554A2 (pt) 2013-05-07
KR20090039735A (ko) 2009-04-22
IL196587A0 (en) 2009-11-18
MA30643B1 (fr) 2009-08-03
CA2659055A1 (en) 2008-01-31
ATE485270T1 (de) 2010-11-15
TW200821286A (en) 2008-05-16
EP2066628A1 (en) 2009-06-10
MX2009000830A (es) 2009-02-03
AU2007276885A1 (en) 2008-01-31
DK2066628T3 (da) 2011-02-07
US20090176804A1 (en) 2009-07-09
GT200900016A (es) 2010-10-13
NO20090862L (no) 2009-02-24
AR062051A1 (es) 2008-08-10

Similar Documents

Publication Publication Date Title
MX2008016423A (es) Arilamidas sustituidas con tetrazol.
HRP20090235A2 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
IL188453A0 (en) Cyclic anilino-pyridinotriazines
AR077014A1 (es) Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AR065810A1 (es) Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
UA94833C2 (en) Substituted bicyclolactams
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
PL2114933T3 (pl) Piperydyny jako agoniści GPCR
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
MX2009012125A (es) Compuestos terapeuticos.
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
MY149400A (en) Bridged six-membered ring compounds
GB0607954D0 (en) Organic compounds
AR076362A1 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras.
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
TW200726739A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
MX2009008028A (es) Agentes antiparasitarios.

Legal Events

Date Code Title Description
FC Application refused